

Electronic supplementary material (ESM)

Supplementary materials

Table S1. Oligonucleotide sequences

Accession number	Target gene (size)	Primer name	Sequence (5'- to 3'-)	Oligo used for	
NM_007343.3	<i>PRSS3-V1/TRY4</i> (124 bp)	<i>V1</i>	F CTGCGAGGCGCTGGG	RT-PCR	
			R GCAGAAGTGGGAGCCAGAAT		
NM_002771.3	<i>PRSS3-V2</i> (140 bp)	<i>V2</i>	F ATCCTTGCCTTTGTGGGAGC		
			R GCAGAAGTGGGAGCCAGAAT		
NM_001197097.2	<i>PRSS3-V3</i> (129 bp)	<i>V3</i>	F GTGCGCCATTGGTTTTCCAT		
			R GCAGAAGTGGGAGCCAGAAT		
NM_001197098.1	<i>PRSS3-V4</i> (131 bp)	<i>V4</i>	F CGACTCGCATGGGACCTG		
			R GCAGAAGTGGGAGCCAGAAT		
<i>PRSS3</i> - Common Region (101 bp)		<i>Vc</i>	F ATTCTGGCTCCCACTTCTGC		
			R CTCTCCCAGTCTCACCTGGA		
NM_002046	GAPDH (189 bp)	<i>GAPDH</i>	F GAGGCGGAGGAGAACAAACA	MSP	
			R CCATGGAGAAGGCTGGG		
NC_000009.12 (33750466 to 33799231)	<i>PRSS3</i> (152 bp)	<i>MF</i>	GGTACGCGGATAGGGAGGGGATATC		
		<i>MR</i>	TAATATACGCATCGATACCGCAACCCG		
	<i>PRSS3</i> (155 bp)	<i>UF</i>	GGGTATGTGGATAGGGAGGGGATATT		
		<i>UR</i>	AATAATATACACATCAATACCACAACCCA		
<i>PRSS3</i> (286 bp)	<i>BF</i>	TTGATTTGTATGGGATTTGTGG	BQ		
	<i>BR</i>	ACCTTCCCCTCACCTACAAC			
NM_007343.3	<i>PRSS3</i>	<i>PRSS3/TRY4</i>	F GGAGGATGTGCGGACCTGACGACAG		cDNA construct
			R GATCTTAGCTGTTGGCAGCGATGGTGTCTT		
<i>PRSS3</i> - Common Region		<i>siPRSS3-1</i>	GGGACACUCUGGACAAUGA		RNA inference
		<i>siPRSS3-2</i>	GAUCAUCCGCCACCCUAAA		

GAPDH: glyceraldehyde-3-phosphate dehydrogenase; F: forward; R: reverse; M: methylated, U: unmethylated.

Supplementary Figure




Fig. S1 A. Alignment of the amino acid sequences of the PRSS3 isoforms. The sequences highlighted in gray indicate the identical sequences among the isoforms. The underlined sequences indicate a signal peptide. B. A schematic representation of the human *PRSS3* gene illustrating the existence of exons for each transcript variant. The position of RT-PCR primers is indicated by black arrows. C. The mRNA expression of PRSS3 variants in human HCC and pancreatic cancer cell lines analyzed by semi-quantitative RT-PCR. The constituent and abundant expression of *PRSS3* in pancreatic cancer cell lines was selected as endogenous internal controls to ensure assay reliability. V1-V4: the RT-PCR products of PRSS3-V1 to V4; GAPDH: the internal control.